Summary
Sitagliptin is a once-daily oral medication in the depeptidyl-peptidase-4 (DPP-4) inhibitor class of medications. This article discusses data from a phase 3 non-inferiority trial of sitagliptin versus glipizide.
- diabetes & endocrinology clinical trials
- diabetes mellitus
- © 2006 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.